ObjectivesTo assess clinical activity, ultrasound synovitis and drug levels in rheumatoid arthritis (RA) patients receiving anti-TNFα therapy with extended interval of administration (EIA).MethodsProspective observational study. Population: RA patients, in clinical remission, receiving adalimumab (ADL) or etanercept (ETN) with EIA. Clinical activity was assessed by DAS28-ESR, DAS28-CRP, CDAI and SDAI scores at each visit. Twelve-joint ultrasound assessment (elbows, wrists, 2nd and 3rd metacarpophalangeal joints, knees and ankles) was performed evaluating synovitis through B-mode (BM) and Color Doppler signal (CD). A BM and CD score was calculated summing the highest score from each joint to a maximum of 36 points. We consider positive score >1 point. Serum drug levels were measured using Promonitor® ELISA kits (Progenika Biopharma-Grifols, Spain).ResultsA total of 39 patients were included since February 2011 to December 2016. One patient was excluded due to blindness violation and 2 patients never reduced anti-TNFα due to low drug levels. 31 patients were women (82%) and the mean age was 61 (39–81) years. Most patients were RF positive (87%) and ACPA positive (74%). 22 patients were with ADL treatment and 16 with ETN. 32 patients (82%) were with DMARD concomitant treatment (18 MTX (46%), 11 LEF (18%), 2 HCQ (5%), 1 SSZ (2%)) and 7 patients were with low-dose CS (18%). Mean time from diagnosis was 14,95 years (range 2,15 – 52,31) and Mean time with current biologic drug was 4,21 years (range 1,39 – 11,07). Nine patients (24%) returned to standard interval due to worsening of clinical activity and one discontinued treatment due to septic arthritis. All of them returned to clinical remission and no anti-drug antibodies were detected. Clinical activity scores, ultrasound scores and drug levels are summarized in table 1.Table 1.Clinical activity scores, ultrasound scores and drug levelsBasal visit6 months12 months N323120DAS28-ESR2,0 (0,91)1,83 (0,83)1,61 (0,70)DAS28-CRP1,71 (0,51)1,78 (0,52)1,62 (0,48)SDAI4,25 (2,55)4,27 (3,04)3,64 (3,13)CDAI3,82 (2,48)3,61 (2,33)2,76 (1,3)BM score3,57 (4,57)3,29 (3,81)4,7 (4,32)CD score0,78 (0,80)1,19 (1,7)1,15 (1,42)BM score (%)73,9177,4290,00CD score (%)56,5245,1650,00ETN4,61 (2,743,59 (2,9)3,03 (0,84)ADL12,05 (6,88)8,49 (5,01)6,49 (2,78)**p<0,05. All results mean (SD) otherwise specified.Conclusions1. Clinical remission was sustained in most patients receiving ADL or ETN in extended interval of administration (EIA). 2. Drug levels decrease over time. 3. Some patients (24%) returned to standard interval of administration due to clinical worsening. 4. Some patients show subclinical ultrasound synovitis in B-mode (90%) or Color Doppler (50%) 5. It would be advisable to perform periodic ultrasound and monitoring of anti-TNFα levels to maintain clinical remission in patients with EIA.AcknowledgementsThis study was supported by a research grant from Fundaciόn Española de Reumatología and AIRE-MB.Disclosure of InterestJ. Senabre Gallego Speakers bureau: MSD, Novartis, Abbvie, UCB, BMS,...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.